Bär & Karrer Ltd. | View firm profile
Novartis Finance S.A. completed the placement
of EUR 750,000,000 Guaranteed Notes due 2023, EUR 750,000,000 Guaranteed Notes
due 2030 and EUR 750,000,000 Guaranteed Notes due 2038. The 2023 Notes were
issued at 99.655% of their principal amount with an interest of 0.500% and will
mature on 14 August 2023 at their nominal value. The 2030 Notes were issued at
99.957% of their principal amount with an interest of 1.375% and will mature on
14 August 2030. The 2038 Notes were issued at 99.217% of their principal amount
with an interest of 1.700% and will mature on 14 August 2038. The Notes are
guaranteed by Novartis AG. They have been provisionally admitted to trading at
the SIX Swiss Exchange and are expected to be listed there as well.
Novartis Finance S.A. completed the placement
of EUR 750,000,000 Guaranteed Notes due 2023, EUR 750,000,000 Guaranteed Notes
due 2030 and EUR 750,000,000 Guaranteed Notes due 2038. The 2023 Notes were
issued at 99.655% of their principal amount with an interest of 0.500% and will
mature on 14 August 2023 at their nominal value. The 2030 Notes were issued at
99.957% of their principal amount with an interest of 1.375% and will mature on
14 August 2030. The 2038 Notes were issued at 99.217% of their principal amount
with an interest of 1.700% and will mature on 14 August 2038. The Notes are
guaranteed by Novartis AG. They have been provisionally admitted to trading at
the SIX Swiss Exchange and are expected to be listed there as well.
Barclays Bank PLC, BNP Paribas and Deutsche
Bank AG, London Branch acted as Joint Lead Managers and HSBC Bank plc, Société
Générale and The Royal Bank of Scotland plc (trading as NatWest Markets) as
Co-Managers.
Bär & Karrer acted as Swiss legal advisor
to Novartis in this transaction. The team included Thomas U. Reutter, Alexander
von Jeinsen and Daniel Raun (all Capital Markets) as well as Susanne Schreiber
and Cyrill Diefenbacher (both Tax).